Emedastinum [INN-Latin]
Emedastinum [INN-Latin] Brand names, Emedastinum [INN-Latin] Analogs
Emedastinum [INN-Latin] Brand Names Mixture
- No information avaliable
Emedastinum [INN-Latin] Chemical_Formula
C22H23N3O4
Emedastinum [INN-Latin] RX_link
http://www.rxlist.com/cgi/generic4/tarceva.htm
Emedastinum [INN-Latin] fda sheet
Emedastinum [INN-Latin] msds (material safety sheet)
Emedastinum [INN-Latin] Synthesis Reference
No information avaliable
Emedastinum [INN-Latin] Molecular Weight
393.436 g/mol
Emedastinum [INN-Latin] Melting Point
No information avaliable
Emedastinum [INN-Latin] H2O Solubility
Very slightly soluble (hydrochloride salt - maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2)
Emedastinum [INN-Latin] State
Solid
Emedastinum [INN-Latin] LogP
3.126
Emedastinum [INN-Latin] Dosage Forms
Tablet (27.3 mg, 109.3 mg or 163.9 mg)
Emedastinum [INN-Latin] Indication
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Emedastinum [INN-Latin] Pharmacology
Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase inhibitor.
Emedastinum [INN-Latin] Absorption
Erlotinib is about 60% absorbed after oral administration and its bioavailability is substantially increased by food to almost 100%.
Emedastinum [INN-Latin] side effects and Toxicity
Symptoms of overdose include diarrhea, rash, and liver transaminase elevation.
Emedastinum [INN-Latin] Patient Information
Emedastinum [INN-Latin] Organisms Affected
Humans and other mammals
